Modern Approaches for Antiandrogen-Resistant Prostate Cancer Therapy
Abstract
:Introduction
Discussions
The Immune Checkpoint Inhibitor therapy (CPi) and Poly ADP-Ribose Polymerase inhibitors (PARPi)
Local experimental procedures
Highlights
- ✓
- Prostate cancer still poses difficulties in predicting the evolution pattern.
- ✓
- Research focused on proteomics provides new therapy approaches on cancer in general and on prostate cancer, in particular.
- ✓
- Immunotherapy with Immune Checkpoint Inhibitor therapy (CPi) and Poly ADP-Ribose Polymerase inhibitors (PARPi) seem to improve difficult-to-treat types of prostate cancer.
- ✓
- Local ablative techniques using imaging guidance improve not only the outcome of patients, but positively influence their ECOG (Eastern Cooperative Oncology Group) performance status.
Conclusions
Conflicts of Interest disclosure
Compliance with ethical standards
References
- Pernar, C.H.; Ebot, E.M.; Wilson, K.M.; Mucci, L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018, 8, a030361. [Google Scholar] [CrossRef] [PubMed]
- Laura, M.; Dana Lucia, S.; Andreea, D.G.; Felix, V.; Adrian, P.S.; Silviu, P.; Camelia, C.D.; Irinel Raluca, P.; Anca Pantea, S.; Corina Silvia, P.; et al. Incidenced of Chemotherapy Induced Paripheral Neuropathy in Cancer Patients in clinical Practice. Farmacia 2018, 66, 904–908. [Google Scholar]
- Markozannes, G.; Tzoulaki, I.; Karli, D.; Evangelou, E.; Ntzani, E.; Gunter, M.J.; Norat, T.; Ioannidis, J.P.; Tsilidis, K.K. Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence. Eur J Cancer. 2016, 69, 61–69. [Google Scholar] [CrossRef] [PubMed]
- Sonn, G.A.; Aronson, W.; Litwin, M.S. Impact of diet on prostate cancer: A review. Prostate Cancer Prostatic Dis. 2005, 8, 304–310. [Google Scholar] [CrossRef] [PubMed]
- Long, J.; Lin, J.; Wang, A.; Wu, L.; Zheng, Y.; Yang, X.; Wan, X.; Xu, H.; Chen, S.; Zhao, H. PD-1/PD-L blockade in gastrointestinal cancers: Lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017, 10, 146. [Google Scholar] [CrossRef]
- Hughes, C.; Murphy, A.; Martin, C.; Sheils, O.; O’Leary, J. Molecular pathology of prostate cancer. J Clin Pathol. 2005, 58, 673–684. [Google Scholar] [CrossRef]
- Mazilu, L.; Suceveanu, A.I.; Tomescu, D.; Ciufu, N.; Baz, R.; Suceveanu, A.P.; Parepa, I.R.; Tofolean, D.E.; Voinea, F. Optimizing the indication for breast-conservative surgery (BCS) in patients with locally-advanced breast cancer. Chirurgia 2013, 108, 478–481. [Google Scholar]
- Suceveanu, A.I.; Micu, I.S.; Baltatescu, G.I.; Petcu, L.; Dobrin, N.; Brinzan, C.; Nitipir, C.; Mazilu, L.; Botea, F.; Herlea, V.; et al. Overexpression of Survivin- 1, TAG-72 si HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea Coast geographical area. Exp. Ther. Med. 2021, 21. [Google Scholar] [CrossRef]
- Iorga, L.; Marcu, D.R.; Diaconu, C.C.; et al. Penile carcinoma and HPV infection (Review). Exp. Ther. Med. 2019, 20, 91–96. [Google Scholar] [CrossRef]
- Li, A.; Yi, M.; Qin, S.; Chu, Q.; Luo, S.; Wu, K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019, 12, 98. [Google Scholar] [CrossRef]
- Marin-Acevedo, J.A.; Soyano, A.E.; Dholaria, B.; Knutson, K.L.; Lou, Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018, 11, 8. [Google Scholar] [CrossRef]
- Bhatia, A.; Kumar, Y. Cellular and molecular mechanisms in cancer immune escape: A comprehensive review. Expert Rev Clin Immunol. 2014, 10, 41–62. [Google Scholar] [CrossRef] [PubMed]
- Lowery, M.A.; Kelsen, D.P.; Capanu, M.; Smith, S.C.; Lee, J.W.; Stadler, Z.K.; Moore, M.J.; Kindler, H.L.; Golan, T.; Segal, A.; et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer 2018, 89, 19–26. [Google Scholar] [CrossRef]
- Swisher, E.M.; Lin, K.K.; Oza, A.M.; Scott, C.L.; Giordano, H.; Sun, J.; Konecny, G.E.; Coleman, R.L.; Tinker, A.V.; O’Malley, D.M.; et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017, 18, 75–87. [Google Scholar] [CrossRef] [PubMed]
- Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017, 377, 523–533. [Google Scholar] [CrossRef]
- Pujade-Lauraine, E.; Ledermann, J.A.; Selle, F.; Gebski, V.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Poveda, A.; Pignata, S.; et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18, 1274–1284. [Google Scholar] [CrossRef] [PubMed]
- Mirza, M.R.; Monk, B.J.; Herrstedt, J.; Oza, A.M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J.A.; Lorusso, D.; Vergote, I.; et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016, 375, 2154–2164. [Google Scholar] [CrossRef]
- Turner, N.C.; Telli, M.L.; Rugo, H.S.; Mailliez, A.; Ettl, J.; Grischke, E.M.; Mina, L.A.; Balmaña, J.; Fasching, P.A.; Hurvitz, S.A.; et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019, 25, 2717–2724. [Google Scholar] [CrossRef]
- Karzai, F.; VanderWeele, D.; Madan, R.A.; Owens, H.; Cordes, L.M.; Hankin, A.; Couvillon, A.; Nichols, E.; Bilusic, M.; Beshiri, M.L.; et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018, 6, 141. [Google Scholar] [CrossRef]
- Abida, W.; Cheng, M.L.; Armenia, J.; Middha, S.; Autio, K.A.; Vargas, H.A.; Rathkopf, D.; Morris, M.J.; Danila, D.C.; Slovin, S.F.; et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019, 5, 471–478. [Google Scholar] [CrossRef]
- Rebello, R.J.; Oing, C.; Knudsen, K.E.; Loeb, S.; Johnson, D.C.; Reiter, R.E.; Gillessen, S.; Van der Kwast, T.; Bristow, R.G. Prostate cancer. Nat Rev Dis Primers. 2021, 7, 9. [Google Scholar] [CrossRef] [PubMed]
- Ramsay, C.R.; Adewuyi, T.E.; Gray, J.; Hislop, J.; Shirley, M.D.; Jayakody, S.; MacLennan, G.; Fraser, C.; MacLennan, S.; Brazzelli, M.; et al. Ablative therapy for people with localised prostate cancer: A systematic review and economic evaluation. Health Technol Assess. 2015, 19, 1–490. [Google Scholar] [CrossRef] [PubMed]
- Yutkin, V.; Ahmed, H.U.; Donaldson, I.; McCartan, N.; Siddiqui, K.; Emberton, M.; Chin, J.L. Salvage high- intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy. Urology 2014, 84, 1157–1162. [Google Scholar] [CrossRef] [PubMed]
- Motofei, I.G. The etiology of premature ejaculation starting from a bihormonal model of normal sexual stimulation. Int J Impot Res. 2001, 13, 49–50. [Google Scholar] [CrossRef]
- Sung, H.H.; Jeong, B.C.; Seo, S.I.; Jeon, S.S.; Choi, H.Y.; Lee, H.M. Seven years of experience with high-intensity focused ultrasound for prostate cancer: Advantages and limitations. Prostate. 2012, 72, 1399–1406. [Google Scholar] [CrossRef]
- Thüroff, S.; Chaussy, C. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol. 2013, 190, 702–710. [Google Scholar] [CrossRef]
- Uchida, T.; Nakano, M.; Hongo, S.; Shoji, S.; Nagata, Y.; Satoh, T.; Baba, S.; Usui, Y.; Terachi, T. High-intensity focused ultrasound therapy for prostate cancer. Int J Urol. 2012, 19, 187–201. [Google Scholar] [CrossRef] [PubMed]
- Bahn, D.K.; Lee, F.; Badalament, R.; Kumar, A.; Greski, J.; Chernick, M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002, 60 (Suppl. 1), 3–11. [Google Scholar] [CrossRef]
- Balalau, C.; Voiculescu, S.; Motofei, I.; Scaunasu, R.V.; Negrei, C. Low dose tamoxifen as treatment of benign breast proliferative lesions. Farmacia. 2015, 63, 371–375. [Google Scholar]
- Long, J.P.; Bahn, D.; Lee, F.; Shinohara, K.; Chinn, D.O.; Macaluso, J.N., Jr. Five-year retrospective, multi- institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001, 57, 518–523. [Google Scholar] [CrossRef]
- Pantea-Stoian, A.; Pituru, S.M.; Hainarosie, R.; Andronache, L.F.; Ginghina, O.; Sarafinceanu, C. Testosterone therapy, new opportunities in diabetes mellitus. Farmacia 2018, 66, 1–7. [Google Scholar]
- Cozaru, G.C.; Papari, A.C.; Sandu, M.L. The effects of psycho-education and counselling for women suffering from breast cancer in support groups. Procedia-Soc. Behav. Sci. 2014, 128, 10–15. [Google Scholar] [CrossRef]
- Donnelly, B.J.; Saliken, J.C.; Brasher, P.M.; Ernst, S.D.; Rewcastle, J.C.; Lau, H.; Robinson, J.; Trpkov, K. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010, 116, 323–330. [Google Scholar] [CrossRef] [PubMed]
- Oto, A.; Sethi, I.; Karczmar, G.; McNichols, R.; Ivancevic, M.K.; Stadler, W.M.; Watson, S.; Eggener, S. MR imaging- guided focal laser ablation for prostate cancer: Phase I trial. Radiology 2013, 267, 932–940. [Google Scholar] [CrossRef] [PubMed]
- Woodrum, D.A.; Gorny, K.R.; Mynderse, L.A. MR-Guided Prostate Interventions. Top Magn Reson Imaging 2018, 27, 141–151. [Google Scholar] [CrossRef]
- Walser, E.; Nance, A.; Ynalvez, L.; Yong, S.; Aoughsten, J.S.; Eyzaguirre, E.J.; Williams, S.B. Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease. J Vasc Interv Radiol. 2019, 30, 401–409.e2. [Google Scholar] [CrossRef]
- Eggener, S.E.; Yousuf, A.; Watson, S.; Wang, S.; Oto, A. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016, 196, 1670–1675. [Google Scholar] [CrossRef]
- Brînzan, C.; Aşchie, M.; Matei, E.; Mitroi, A.; Cozaru, G. Molecular expression profiles of selected microRNAs in colorectal adenocarcinoma in patients from southeastern part of Romania. Medicine 2019, 98. [Google Scholar] [CrossRef]
© 2021 by the author. 2021 Felix Voinea, Laura Mazilu, Ioan Sergiu Micu, Adrian Paul Suceveanu, Madalina Iliescu, Andrada Dumitru, Vlad Denis Constantin, Ioana Paunica, Andra Iulia Suceveanu
Share and Cite
Voinea, F.; Mazilu, L.; Micu, I.S.; Suceveanu, A.P.; Iliescu, M.; Dumitru, A.; Constantin, V.D.; Paunica, I.; Suceveanu, A.I. Modern Approaches for Antiandrogen-Resistant Prostate Cancer Therapy. J. Mind Med. Sci. 2021, 8, 71-75. https://doi.org/10.22543/7674.81.P7175
Voinea F, Mazilu L, Micu IS, Suceveanu AP, Iliescu M, Dumitru A, Constantin VD, Paunica I, Suceveanu AI. Modern Approaches for Antiandrogen-Resistant Prostate Cancer Therapy. Journal of Mind and Medical Sciences. 2021; 8(1):71-75. https://doi.org/10.22543/7674.81.P7175
Chicago/Turabian StyleVoinea, Felix, Laura Mazilu, Ioan Sergiu Micu, Adrian Paul Suceveanu, Madalina Iliescu, Andrada Dumitru, Vlad Denis Constantin, Ioana Paunica, and Andra Iulia Suceveanu. 2021. "Modern Approaches for Antiandrogen-Resistant Prostate Cancer Therapy" Journal of Mind and Medical Sciences 8, no. 1: 71-75. https://doi.org/10.22543/7674.81.P7175
APA StyleVoinea, F., Mazilu, L., Micu, I. S., Suceveanu, A. P., Iliescu, M., Dumitru, A., Constantin, V. D., Paunica, I., & Suceveanu, A. I. (2021). Modern Approaches for Antiandrogen-Resistant Prostate Cancer Therapy. Journal of Mind and Medical Sciences, 8(1), 71-75. https://doi.org/10.22543/7674.81.P7175